TABLE VII.

Randomized controlled trials for treatment of cancer-related venous thromboembolism (vte)

Trial	Patients (n)	Regimen		Duration of treatment	Outcome	Incidences
		Study	Control			vte			Major bleeding
						Study (%)	Control (%)	p Value	Study (%)	Control (%)	p Value
Meyer et al., 2002 54	146	Enoxaparin 1.5 mg/kg daily	Enoxaparin 1.5 mg/kg daily for 5–7 days, then warfarin at inr 2–3	3 Months	Combined recurrent vte and hemorrhage	10.5a	21.1a	0.09a	7.0	16.0	0.09
Lee et al., 2003 53	672	Dalteparin 200 IU/kg daily for 1 month, then 150 IU/kg daily for 5 months	Dalteparin 200 IU/kg daily for 5–7 days, then warfarin at inr 2–3	As described in “Regimen”	Recurrent vte	9.0	17.0	0.002	6	4	0.27
Deitcher et al., 2006 55	122	Enoxaparin 1 mg/kg twice daily, then 1.0 mg/kg daily or 1.5 mg/kg daily	Enoxaparin 1 mg/kg twice daily, then warfarin at inr 2–3	5 Days at twice daily, then 6 months	Recurrent vte	6.9 (1 mg), 6.3 (1.5 mg)	10.00	>0.05	6.5 (1 mg), 11.1 (1.5 mg)	2.90	>0.05
Hull et al., 2006 56	200	Tinzaparin 175 IU/kg daily	ufh infusion then warfarin at inr 2–3	3 Months	Recurrent vte	6.0b	10.0b	>0.05b	7.0	7.0	>0.05

^aCombined 3-month incidence of patients with either recurrent venous thromboembolism or major bleeding.

^b3-Month incidence of patients with recurrent venous thromboembolism.

vte = venous thromboembolism; inr = international normalized ratio.